{"id":"NCT01022580","sponsor":"Roberta Ballard","briefTitle":"Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia","officialTitle":"Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia: A Study in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2013-12","completion":"2016-01","firstPosted":"2009-12-01","resultsPosted":"2021-05-13","lastUpdate":"2021-05-13"},"enrollment":511,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Bronchopulmonary Dysplasia"],"interventions":[{"type":"DRUG","name":"Infasurf surfactant (ONY, Inc.)","otherNames":["Treatment"]},{"type":"DRUG","name":"Sham (No Treatment)","otherNames":["Control"]}],"arms":[{"label":"Infasurf surfactant (ONY, Inc.)","type":"ACTIVE_COMPARATOR"},{"label":"Sham (No Treatment)","type":"SHAM_COMPARATOR"}],"summary":"The purpose of this study is to determine if late doses of Infasurf surfactant given when patients are receiving inhaled nitric oxide will interact to improve surfactant function and increase survival without BPD in treated infants.","primaryOutcome":{"measure":"Survival Without BPD at 36 Weeks Post Menstrual Age.","timeFrame":"36 weeks post menstrual age +/- 1 week","effectByArm":[{"arm":"Infasurf Surfactant (ONY, Inc.)","deltaMin":79,"sd":null},{"arm":"Sham","deltaMin":82,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.89"}]},"eligibility":{"minAge":"7 Days","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":21,"countries":["United States"]},"refs":{"pmids":["16870913","17671061","17403837","26500107","29627188","28100402","27583380"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":252},"commonTop":["Sepsis","PDA Requiring Treatment","IVH New or Worsened","ROP Class 4-5 or surgery","NEC"]}}